T 0386/94 (Chymosin) du 11.01.1996
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:1996:T038694.19960111
- Date de la décision
- 11 janvier 1996
- Numéro de l'affaire
- T 0386/94
- Requête en révision de
- -
- Numéro de la demande
- 82201272.0
- Classe de la CIB
- C12N 15/00
- Langue de la procédure
- Anglais
- Distribution
- Publiées au Journal officiel de l'OEB (A)
- Téléchargement
- Décision en anglais
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- -
- Titre de la demande
- DNA molecules comprising the genes for preprochymosin and its maturation forms, and microorganisms transformed thereby
- Nom du demandeur
- UNILEVER N.V.
- Nom de l'opposant
- Celltech Limited
Chr. Hansens Laboratorium A/S - Chambre
- 3.3.04
- Sommaire
Inventive step may be acknowledged in the field of gene technology if there is no reasonable expectation of success that the cloning and expression of a given gene can be carried out. However, in a case where, at the priority date, a skilled person can expect to perform the cloning and expression of a gene in a fairly straightforward manner, and the cloning, although requiring much work, does not pose such problems as to prove that the expectation of success was ill-founded, inventive step cannot be acknowledged.
- Dispositions juridiques pertinentes
- European Patent Convention Art 123(2) 1973European Patent Convention Art 123(3) 1973European Patent Convention Art 54(3) 1973European Patent Convention Art 54(4) 1973European Patent Convention Art 56 1973European Patent Convention Art 83 1973European Patent Convention Art 84 1973European Patent Convention Art 87 1973European Patent Convention Art 88 1973
- Mots-clés
- Sufficiency of disclosure (yes)
Novelty (yes)
Inventive step (no) - Exergue
- -
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.
3. The request for reimbursement of the appeal fee is rejected.